摘要
目的探讨经肝动脉灌注栓塞术(TACE)联合CT导向下放射性125I粒子瘤内植入治疗肝癌的疗效。方法回顾性分析75例确诊为原发性肝癌的患者,A组41例(单纯TACE组),B组34例(TACE序贯125I粒子植入术组),两组均于术后第3、6、12个月行CT扫描进行疗效评价,分别比较两组术后6个月、12个月的生存状态。两组有效率及生存状态比较均采用卡方检验,以P<0.05为差异有统计学意义。结果术后3个月,A、B组的总体有效率(CR+PR)分别为36.6%(15/41)、70.6%(24/34),差异有统计学意义(P=0.005);B组术后6个月、1年生存率分别为97.1%(33/34)、85.3%(29/34),明显高于A组的73.2%(30/41)、41.5%(17/41)(P<0.01)。结论 TACE联合CT导向下放射性125I粒子瘤内植入是治疗肝癌的安全有效的方法,具有良好的应用前景。
Objective Objective To investigate the technical points and the clinical effectiveness of transcatheter arterial chemoembolization （TACE） combined with CT-guided ^125I seeds implantation for the treatment of liver cancer. Methods 75 cases of hepatic carcinoma were retrospectively collected and divided into group A （41 patients with TACE alone） and group B （35 patients with TACE combined with ^125I seeds implantation sequential therapy）. Efficacy evaluation was performed in 3 month, 6 month and 1 year after the operation by CT scan, and the survival status of 6 month and 1 year were also recorded. Results The overall response （ CR ＋ PR） of group A and group B were 36.6% （ 15/41 ） and 70.6% （24/34） respectively at 3 months after operation with significant difference （ P = 0. 005 ）. The survival rate at 6 and 12 months in group B （97.1% and 85.3% ） were significantly higher than those in group A （73.2% and 41.5% ） （P 〈0.01 ）. Conclusion TACE combined with CT-guided t2sI seeds implantation could be a safe and effective treatment for liver cancer.
出处
《标记免疫分析与临床》
CAS
2013年第4期207-209,共3页
Labeled Immunoassays and Clinical Medicine
